Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
NCT ID NCT06294236
First seen Dec 18, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the disease. Participants receive the cells after a short chemotherapy course to prepare their bodies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Swedish Medical Center
Seattle, Washington, 98122, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SC291 (a type of CAR T cell therapy made from donor cells)
What this could lead to
If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 7 participants, so safety and effectiveness are not yet proven. There may be serious side effects, and the treatment may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.